npj Vaccines (Dec 2024)

Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron

  • Paolla Beatriz Almeida Pinto,
  • Julia Timis,
  • Kantinan Chuensirikulchai,
  • Qin Hui Li,
  • Hsueh Han Lu,
  • Erin Maule,
  • Michael Nguyen,
  • Rúbens Prince dos Santos Alves,
  • Shailendra Kumar Verma,
  • Fernanda Ana-Sosa-Batiz,
  • Kristen Valentine,
  • Sara Landeras-Bueno,
  • Kenneth Kim,
  • Kathryn Hastie,
  • Erica Ollmann Saphire,
  • Ada Alves,
  • Annie Elong Ngono,
  • Sujan Shresta

DOI
https://doi.org/10.1038/s41541-024-01043-3
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 15

Abstract

Read online

Abstract The continuing evolution of SARS-CoV-2 variants challenges the durability of existing spike (S)-based COVID-19 vaccines. We hypothesized that vaccines composed of both S and nucleocapsid (N) antigens would increase the durability of protection by strengthening and broadening cellular immunity compared with S-based vaccines. To test this, we examined the immunogenicity and efficacy of wild-type SARS-CoV-2 S- and N-based DNA vaccines administered individually or together to K18-hACE2 mice. S, N, and S + N vaccines all elicited polyfunctional CD4+ and CD8+ T cell responses and provided short-term cross-protection against Beta and Omicron BA.2 variants, but only co-immunization with S + N vaccines provided long-term protection against Omicron BA.2. Depletion of CD4+ and CD8+ T cells reduced the long-term efficacy, demonstrating a crucial role for T cells in the durability of protection. These findings underscore the potential to enhance long-lived protection against SARS-CoV-2 variants by combining S and N antigens in next-generation COVID-19 vaccines.